Methods for claims-based pharmacoeconomic studies in psychosis

PharmacoEconomics

Volumn 20, Issue 8, 2002, Pages 499-511

  Gianfrancesco, F ^a   Wang, R H ^a   Mahmoud, R ^b   White, R ^c  

^a HECON Associates Inc   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; RISPERIDONE;

DISEASE SEVERITY; HEALTH CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; PHARMACOECONOMICS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

EID: 0036327510     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220080-00001     Document Type: Review

References (29)

1. Methodological hurdles in conducting pharmacoeconomic analyses
2. Common errors and controversies in pharmacoeconomic analyses
3. Guidelines for pharmacoeconomic studies: Recommendations from the panel on cost effectiveness in health and medicine
4. Problems in conducting economic evaluations alongside clinical trials: Lessons from a study of case management for people with mental disorders
5. Practical issues in conducting phanmacoeconomic studies
6. Cost-effectiveness comparisons using 'real world' randomized trials: The case of new antidepressant drugs
7. Economic analysis alongside clinical trials
8. Using healthcare claims data for outcomes research and pharmacoeconomic analyses
9. The use of claims databases for outcomes research: Rationale, challenges, and strategies
10. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia
11. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health Linkable Databases
12. Impact of risperidone on the use of mental health care resources
13. Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah
14. Risperidone: Clinical outcome predictors and cost-effectiveness in a naturalistic setting
15. Economic outcomes of antipsychotic agents in a Medicaid population: Traditional agents vs risperidone
16. Treatment costs and patient outcomes with use of risperidone in a public mental health setting
17. Use of health care services by patients treated with risperidone vs conventional antipsychotic agents
18. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
19. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study
20. Pharmacoeconomics of antipsychotic drug therapy
21. Changing antipsychotic medication: Guidelines on the transition to treatment with risperidone
22. Novel antipsychotics and the new onset diabetes
23. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia
24. Association of new-onset diabetes and antipyschotics: Findings from a large health plan database
25. A comparison of alternative models for the demand for medical care
26. Choosing between the sample-selection model and the multi-part model
27. Methods for comparison of cost data
28. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data